Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Arbutus And Barinthus Bio Report IM-PROVE II Trial Data Showing Nivolumab Boosts HBsAg Loss Rates In Chronic Hepatitis B Patients; 23% Achieve HBsAg Loss By Week 48 With Imdusiran, VTP-300, And Low-Dose Nivolumab

Author: Benzinga Newsdesk | November 15, 2024 12:02pm

Posted In: ABUS BRNS